Hambrecht & Quist Capital Management

Summary

In 1968 was created Hambrecht & Quist Capital Management, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the Boston. The venture was found in North America in United States.

The current fund was established by William R. Timken.

Among the most successful fund investment fields, there are Biotechnology, Medical Device. Among the various public portfolio startups of the fund, we may underline Shopzilla, Cygent, Raven Biotechnologies The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The real fund results show that this Corporate Investor is 12 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. This Hambrecht & Quist Capital Management works on 31 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. The increased amount of exits for fund were in 2003. When the investment is from Hambrecht & Quist Capital Management the average startup value is 50-100 millions dollars.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Hambrecht & Quist Capital Management, startups are often financed by Forward Ventures, Enterprise Partners, William Blair. The meaningful sponsors for the fund in investment in the same round are U.S. Venture Partners (USVP), SoftBank, OrbiMed. In the next rounds fund is usually obtained by Granite Ventures, Tekla Capital Management, TCV.